Clinical and Laboratory Study of Lysozyme Deposition on Daily Disposable Contact Lenses

NCT ID: NCT02365298

Last Updated: 2018-06-19

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

28 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-01-01

Study Completion Date

2015-06-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In vitro studies show that some hydrogel materials uptake more lysozyme than other hydrogel materials and that this protein remains largely active and promotes reduced cytokine response in an in vitro culture of human corneal epithelial cells. This study investigates whether these data transfer to the in vivo situation.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Visual Acuity

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

etafilcon A

Worn in a daily disposable modality

Group Type EXPERIMENTAL

etafilcon A

Intervention Type DEVICE

etafilcon A soft contact lens

nelfilcon A

Intervention Type DEVICE

nelfilcon A

nelfilcon A

Worn in a daily disposable modality

Group Type ACTIVE_COMPARATOR

etafilcon A

Intervention Type DEVICE

etafilcon A soft contact lens

nelfilcon A

Intervention Type DEVICE

nelfilcon A

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

etafilcon A

etafilcon A soft contact lens

Intervention Type DEVICE

nelfilcon A

nelfilcon A

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Marketed Investigational Soft Contact Lens Marketed Investigational Soft Contact Lens

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. The subject must read, understand, and sign the Statement of Informed Consent and receive a fully executed copy of the form.
2. The subject must appear able and willing to adhere to the instructions set forth in the clinical protocol.
3. The subject must be willing to follow instructions and maintain the appointment schedule.
4. The subject must be between 18 and 40 years of age (inclusive).
5. The subject's vertex corrected spherical equivalent distance refraction must be in the range of -0.50D to -6.00D in each eye (inclusive).
6. The subject's refractive cylinder must not exceed -1.25DC in each eye after vertexing to the corneal plane.
7. The subject must be a current wearer of spherical, soft contact lenses (no toric, bifocal or multifocal contact lenses, no extended wear or monovision) for at least 5 days/week and at least 8 hours/day during to month prior to enrollment.
8. The subject must own a wearable pair of spectacles and wear them the day of the initial visit.
9. The subject must be an existing wearer of spherical soft contact lenses in both eyes.
10. The subject must have normal eye (i.e., no ocular medications or infections of any type).
11. The subject must be able to wear the study lenses for a minimum seven hours per day.

Exclusion Criteria

1. Any ocular or systemic allergies or diseases that may interfere with contact lens wear (at the investigator's discretion).
2. Any systemic disease, autoimmune disease, or use of medication, which may interfere with contact lens wear (at the investigator's discretion).
3. Currently pregnant or lactating (subjects who become pregnant during the study will be discontinued).
4. Any infectious disease (e.g., hepatitis, tuberculosis) or a contagious immunosuppressive disease.
5. Any active ocular infection.
6. Is using any topical medication including artificial tears (ATS) up to two weeks prior to the screening visit.
7. Any participants whose habitual contact lenses are used as an extended wear regimen.
8. Entropion, ectropion, extrusions, chalazia, recurrent styes, glaucoma, history of recurrent corneal erosions, aphakia, or moderate or above corneal distortion by keratometry.
9. Clinically significant (grade 3 or 4) corneal edema, corneal vascularization, corneal staining, or any other abnormalities of the cornea which would contraindicate contact lens wear; clinically significant (grade 3 or 4) tarsal abnormalities or bulbar injection which might interfere with contact lens wear.
10. Any know hypersensitivity or allergic reaction to study products.
11. Participation in any contact lens or lens care product clinical trial within seven days prior to study enrollment.
12. Employee or family member of the Center for Contact Lens Research (e.g., Investigator, Coordinator, Technician).
Minimum Eligible Age

18 Years

Maximum Eligible Age

40 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Johnson & Johnson Vision Care, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Waterloo

Waterloo, Ontario, Canada

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Canada

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CR-5695

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.